Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
Hepatology
; 79(5): 1048-1064, 2024 May 01.
Article
in En
| MEDLINE
| ID: mdl-37976391
ABSTRACT
BACKGROUND AND AIMS:
Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with terlipressin and albumin, provides survival benefits, but may be associated with cardiopulmonary complications. We analyzed the predictors of terlipressin response and mortality using point-of-care echocardiography (POC-Echo) and cardiac and renal biomarkers.APPROACH:
Between December 2021 and January 2023, patients with HRS-AKI were assessed with POC-Echo and lung ultrasound within 6 hours of admission, at the time of starting terlipressin (48 h), and at 72 hours. Volume expansion was done with 20% albumin, followed by terlipressin infusion. Clinical data, POC-Echo data, and serum biomarkers were prospectively collected. Cirrhotic cardiomyopathy (CCM) was defined per 2020 criteria.RESULTS:
One hundred and forty patients were enrolled (84% men, 59% alcohol-associated disease, mean MELD-Na 25±SD 5.6). A median daily dose of infused terlipressin was 4.3 (interquartile range 3.9-4.6) mg/day; mean duration 6.4 ± SD 1.9 days; the complete response was in 62% and partial response in 11%. Overall mortality was 14% and 16% at 30 and 90 days, respectively. Cutoffs for prediction of terlipressin nonresponse were cardiac variables [ratio of early mitral inflow velocity and mitral annular early diastolic tissue doppler velocity > 12.5 (indicating increased left filling pressures, C-statistic 0.774), tissue doppler mitral velocity < 7 cm/s (indicating impaired relaxation; C-statistic 0.791), > 20.5% reduction in cardiac index at 72 hours (C-statistic 0.885); p < 0.001] and pretreatment biomarkers (CysC > 2.2 mg/l, C-statistic 0.640 and N-terminal proBNP > 350 pg/mL, C-statistic 0.655; p <0.050). About 6% of all patients with HRS-AKI and 26% of patients with CCM had pulmonary edema. The presence of CCM (adjusted HR 1.9; CI 1.8-4.5, p = 0.009) and terlipressin nonresponse (adjusted HR 5.2; CI 2.2-12.2, p <0.001) were predictors of mortality independent of age, sex, obesity, DM-2, etiology, and baseline creatinine.CONCLUSIONS:
CCM and reduction in cardiac index, reliably predict terlipressin nonresponse. CCM is independently associated with poor survival in HRS-AKI.
Full text:
1
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Hepatorenal Syndrome
/
Acute Kidney Injury
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Hepatology
Year:
2024
Document type:
Article